Source comparison
CJC-1295 DAC vs no-DAC: the side-by-side comparison
This is the table the whole article exists to produce. Every figure in the “documented research protocol” rows reflects what our protocol pages document, not a recommendation; every half-life and endocrine-profile figure is sourced. Also called CJC-1295, DAC:G
This comparison does not assign a generated winner or score.
- This is the table the whole article exists to produce. Every figure in the “documented research protocol” rows reflects what our protocol pages document, not a recommendation; every half-life and endocrine-profile figure is sourced.
- Also called
- CJC-1295, DAC:GRF, CJC-1295 DAC
- Mod GRF(1-29), Modified GRF 1-29, tetrasubstituted GRF(1-29)
- Structure
- Tetrasubstituted hGRF(1-29) + Nε-3-maleimidopropionamide lysine at C-terminus[1]
- Tetrasubstituted hGRF(1-29), no linker
- Substitutions
- D-Ala2, Gln8, Ala15, Leu27
- D-Ala2, Gln8, Ala15, Leu27 (identical)
- Binds albumin?
- Yes — covalently, at Cys34
- No
- Half-life
- 5.8–8.1 days (estimated, human)[8]
- Short — minutes. Commonly quoted as ~30 min; not established by any published human PK study we or FDA could locate
- GH profile produced
- Sustained elevation: trough GH ↑7.5-fold, mean GH ↑46%, pulsatility preserved[5]
- Discrete pulse, peak ~15–30 min, back toward baseline within 1–2 h
- IGF-I duration after one dose
- 1.5–3× baseline for 9–11 days; up to 28 days above baseline after multiple doses[8]
- No comparable published multi-day IGF-I data
- Accumulates with repeat dosing?
- Yes — cumulative effect documented[8]
- No meaningful accumulation
- Documented protocol frequency
- Twice weekly
- Once daily (commonly before bed)
- Documented per-injection range
- 300–1,000 mcg
- 100–300 mcg
- Documented weekly total
- ~0.6–2 mg/week
- ~0.7–2.1 mg/week
- Typical reconstitution (5 mg vial)
- 2.0 mL → 2.5 mg/mL (2,500 mcg/mL)
- 3.0 mL → ~1.67 mg/mL (~1,670 mcg/mL)
- 1 unit on a U-100 syringe
- 25 mcg
- ~16.7 mcg
- Human data exists?
- Ascending-dose studies in 63 healthy adults across three papers; the one registered Phase 2 in patients was terminated with no published data[2][11]
- No human studies of any kind identified
- Regulatory status
- Neither is approved for human therapeutic use anywhere. Both are prohibited in sport at all times under WADA S2.
- Notice the trap hidden in the weekly-total row. The two molecules land at roughly the same milligrams per week — around 1–2 mg. That coincidence is why the naming collision persists undetected: someone reading “2 mg per week” can apply it to the wrong molecule and the total will look plausible. It is the distribution across the week that differs completely, and distribution is the whole pharmacology. Two 1,000 mcg DAC injections per week and seven 300 mcg no-DAC injections per week are approximately 2 mg either way, and they are not remotely the same intervention.